Brief: Abeona Therapeutics Holds Pre-IND Meeting With FDA For ABO-701 In Prostate Cancer - SEC Filing
04/06/2026 12:33
BRIEF-Abeona Therapeutics Holds Pre-IND Meeting With FDA For ABO-701 In Prostate Cancer - SEC Filing June 4 (Reuters) - Abeona Therapeutics Inc ABEO.O:
ABEONA THERAPEUTICS - HOLDS PRE-IND MEETING WITH FDA FOR ABO-701 IN PROSTATE CANCER - SEC FILING
ABEONA THERAPEUTICS - TARGETS IND SUBMISSION FOR ABO-701 IN 2027 - SEC FILING
Source text: [ID:n0001493152-26-027197]
Further company coverage: ABEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abeona Therapeutics
See all newsBrief: Abeona Therapeutics Holds Pre-IND Meeting With FDA For ABO-701 In Prostate Cancer - SEC Filing
Abeona Therapeutics posts smaller-than-expected Q1 loss per share
Brief: Abeona Therapeutics® Announces Activation Of Children's Hospital Of Philadelphia As A New Qualified Treatment Center For Zevaskyn®
Abeona rises after adding New York treatment center for gene therapy
Abeona Therapeutics 2025 net income slightly misses estimates on higher SG&A costs